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ABSTRACT
Many challenges arise in candidaemia treatment which involves emergence of antifungal resistance. New species have 
been identified due to improved methods of detection and some are resistant to commonly prescribed antifungal agents such 
as fluconazole and amphotericin B. Therefore, the objective of the study was to observe any changes in the susceptibility 
patterns and distribution of Candida species. This cross sectional study was conducted at the Department of Medical 
Microbiology and Immunology in UKMMC, a tertiary teaching hospital. One hundred and fifty one data were collected 
from the department’s laboratory records from January 2008 to December 2010. The yeasts were identified using ID32C 
carbohydrate assimilation tests whilst the antifungal susceptibility test was performed using Sensititre® YeastOne® 
broth microdilution method. Antifungal agents tested included amphotericin B, fluconazole, itraconazole, voriconazole, 
5-flucytosine and caspofungin. Out of 151 blood isolates, 47 (31.1%) were Candida albicans and 104 (68.9%) were 
non-albicans Candida species. Candida tropicalis has surpassed C. albicans as the most commonly isolated Candida 
species from blood. Overall susceptibility (as compared to 2005-2006 data in brackets) to caspofungin was 99.3% (n/a), 
5-flucytosine 97.4% (98%), amphotericin B 94.7% (100%), voriconazole 92.7% (98%), fluconazole 86.8% (90%) and 
itraconazole 39.1% (40%). In conclusion, although the isolates were generally still susceptible to amphotericin B and 
fluconazole, resistance to these drugs is increasing. 
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ABSTRAK
Banyak cabaran timbul dalam rawatan kandidemia melibatkan kemunculan kerintangan antikulat. Spesies baru telah 
dikenal pasti selaras dengan penambahbaikan kaedah pengenalpastian dan sebahagiannya adalah rintang terhadap 
antikulat yang biasa diberi seperti flukonazol dan amfoterisin B. Oleh itu, tujuan kajian ini adalah untuk memerhati 
sebarang perubahan dalam corak-corak kerentanan dan taburan spesies Candida. Kajian keratan rentas ini telah 
dilakukan di Jabatan Mikrobiologi dan Imunologi Perubatan di PPUKM, sebuah hospital pengajar tertier. Data telah 
dikumpul daripada rekod makmal jabatan dari Januari 2008 hingga Disember 2010. Yis-yis telah dikenal pasti dengan 
menggunakan ujian asimilasi karbohidrat ID32C manakala ujian kerentanan antikulat telah dilakukan dengan kaedah 
pencairan kaldu mikro Sensititre® YeastOne®. Agen-agen antikulat yang diuji termasuk amfoterisin B, flukonazol, 
itrakonazol, vorikonazol, 5-flusitosin dan kaspofungin. Daripada 151 isolat darah, 47 (31.1%) adalah Candida albicans 
dan 104 (68.9%) adalah spesies bukan-albicans Candida. Candida tropicalis telah mengatasi C. albicans sebagai spesis 
Candida yang paling kerap dipencil daripada darah. Kerentanan keseluruhan (dibandingkan dengan data 2005-2006 
dalam kurungan) terhadap kaspofungin adalah 99.3% (n/a), 5-flukitosin 97.4% (98%), amfotericin B 94.7% (100%), 
vorikonazol 92.7% (98%), flukonazol 86.8% (90%) dan itrakonazol 39.1% (40%). Kesimpulannya, walaupun isolat-
isolat secara umumnya masih rentan terhadap amfoterisin B dan flukonazol, kerintangan terhadap ubatan ini semakin 
bertambah. 
Kata kunci:  Candida; Kandidemia; kerentanan antikulat; kerintangan antikulat
INTRODUCTION
Candida species is the fourth most common organism 
associated with bloodstream infections (BSIs) which 
represent the eighth leading cause of death in the world 
(Wenzel & Edmond 2001). In many studies, C. albicans 
had been reported to be the most common Candida 
species responsible for candidaemia (Cuenca-Estrella et 
al. 2002; Takakura et al. 2003; Tortorano et al. 2003; Tzar 
& Shamim 2009; Xess et al. 2007). However, non-albicans 
Candida species (NACs) were also noted to be increasingly 
common especially C. tropicalis, C. parapsilosis and C. 
glabrata (Cuenca-Estrella et al. 2002; Kalkanci et al. 
2007; Takakura et al. 2003; Tortorano et al. 2003; Zepelin 
et al. 2007). 
962
Since these NACs often have variable susceptibilities 
to antifungal agents, it is recommended that every 
healthcare institution have their own local data on 
antifungal susceptibility (Xess et al. 2007). In many 
countries including Malaysia, antifungal susceptibility 
testing is not routinely offered. However, it is becoming 
more relevant nowadays due to various issues such as 
amphotericin B nephrotoxicity, emergence of fluconazole-
resistant isolates and a wider choice of antifungal agents. 
Therefore, this study aimed to investigate changes in the 
local epidemiology and susceptibility patterns of Candida 
species at Universiti Kebangsaan Malaysia Medical Centre 
(UKMMC).
MATERIALS AND METHODS
STUDY POPULATIONS
A cross-sectional study was conducted at the Department 
of Medical Microbiology and Immunology, UKMMC. This 
medical centre is a 1054-bedded, tertiary level teaching 
hospital that provides various medical, surgical and 
intensive care services. The study was carried out from 
January 2008 to December 2010.
DATA COLLECTION
Data were collected from the Mycology Laboratory 
Records, UKMMC. Information collected included month, 
year, laboratory number, medical record number, location 
(ward / clinic), age, sex, race, yeast isolated and antifungal 
susceptibility results. All Candida species isolated from 
the blood cultures from January 2008 to December 2010 
were included in this study with the exception of Candida 
species from the same patient with identical species and 
susceptibility pattern.
YEAST IDENTIfICATION
ID 32C carbohydrate assimilation tests (bioMerieux, Inc., 
USA) were used to identify the yeasts isolates according 
to the manufacturer’s instructions as described previously 
(Tzar & Shamim 2009). 
ANTIfUNgAL SUSCEPTIBILITY TESTINg
Antifungal susceptibility test was performed on all 
Candida species isolated using commercially–prepared 
Sensititre YeastOne YO-8 broth microdilution kit by 
Trek Diagnostic (UK) according to the manufacturer’s 
instructions as described previously (Tzar & Shamim 
2009). The minimal inhibitory concentration (MIC) was 
taken as the lowest antifungal concentration that inhibits 
fungal growth (the first blue well). The MICs were 
interpreted according to the breakpoints provided by 
the Clinical Laboratory and Standards Institute (CLSI). 
The antifungal agents were categorized as susceptible, 
susceptible but dose-dependent (SDD), intermediate or 
resistant. Antifungal agents used were amphotericin B, 
fluconazole, itraconazole, voriconazole, flucytosine and 
caspofungin. 
ETHICAL CONSIDERATIONS
This study was approved by the Research and Ethics 
Committee of Medical faculty, Universiti Kebangsaan 
Malaysia (research code ff-363-2010).
RESULTS
A total of 151 Candida species were identified. More 
Candida isolates were obtained from blood samples 
taken from male patients (95, 63.8% versus 54, 36.2%), 
with a ratio of 1.8:1 (2 missing data). Majority of the 
isolates came from adult patients (18-64 years old), which 
accounted for 105 (69.5%) isolates. The mean age was 46 
years old and the median age was 52. The most common 
age group affected was 51-60 years old (40, 26.5%). Out 
of 151 isolates, 28 (18.5%) were from the elderly patients 
(aged 65 and above) and only 18 (11.9%) came from the 
paediatrics group (aged below 18). four (2.6%) isolates 
came from infants. There were 90 (59.6%) isolates from 
the Malays, 40 (26.5%) from the Chinese, 11 (7.3%) from 
the Indians and 10 (6.6%) from other races. Candida 
albicans showed predilection towards the younger 
age groups while the reverse is true for non-albicans 
Candida species (NAC). Candida albicans accounted 
for 55.6% of candidaemia cases among infants, 38.9% 
among all paediatrics (less than 18 years old), 30.7% 
among adults (18-64 years old) and only 25% among 
elderly (65 years and above). Most isolates of Candida 
were from the Intensive Care Unit 41 (27.2%), surgical 
wards 38 (25.2%), medical wards 34 (22.5%), High 
Dependency Unit 13 (8.6%), Paediatrics wards 6 (4.0%) 
and Paediatrics Intensive Care Unit 5 (3.3%). Three 
isolates were obtained from Bone Marrow Transplant 
Unit, Paediatrics High Dependency Unit and Cardiac 
Care Unit. Two isolates from Obstetrics & gynaecology 
wards and Burns unit and one isolate from the Neonatal 
Intensive Care Unit. Out of 151 blood isolates, 47 (31.1%) 
were Candida albicans and 104 (68.9%) were NAC 
species. Fifty-five (36.4%) isolates were C. tropicalis, 
47 (31.1%) C. albicans, 26 (17.2%) C. parapsilosis, 13 
(8.6%) C. glabrata, 4 (2.6%) C. pelliculosa, 2 (1.3%) C. 
sake, 1 (0.7%) C. krusei, 1 (0.7%) C. globosa, 1 (0.7%) 
C. melibiosica and 1 (0.7%) C. famata. from the total 151 
isolates, 46 (30.5%) were reported in 2008, 67 (44.4%) in 
2009 and 38 (25.1%) in 2010. In 2008, C. albicans was 
still the most common Candida species isolated from 
blood followed by C. tropicalis. However, in 2009, C. 
tropicalis has surpassed C. albicans by almost 20%. This 
trend continued in 2010 although the gap now has reduced 
to about 3%. The trend of Candida species according to 
year is shown in figure I. 
 Among antifungal agents, the overall susceptibility 
(according to MIC90) was highest to caspofungin 99.3%, 
followed by flucytosine 97.3%, amphotericin B 94.7%, 
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voriconazole 92.7%, fluconazole 86.7% and itraconazole 
39.1% (Table 1). Antifungal susceptibility patterns were 
interpreted according to the breakpoints provided by the 
Clinical Laboratory and Standards Institute (CLSI 2008) 
(Table 2). Of all nine fluconazole-resistant isolates, 
100% of them were still susceptible to caspofungin and 
flucytosine and 88.9% to amphotericin B. There was 
marked cross-azole resistance noted in this group where 
none were susceptible to voriconazole, only 25% were 
SDD and 75% were resistant. Similarly for itraconazole; 
none were susceptible, 50% SDD and 50% resistant.
DISCUSSION
Since the introduction of fluconazole in 1990, the 
management of candidaemia has changed tremendously 
resulting in the extensive use of the drug in most countries 
worldwide. The increased fluconazole usage is thought 
to cause a corresponding increase in NAC proportion 
since NACs in general, are relatively less susceptible to 
fluconazole than C. albicans (Playford et al. 2008). More 
than 65% of the candidaemia cases in this study were 
caused by the NACs, compared with 57.5% in our previous 
study (Tzar & Shamim 2009). 
 Majority of (95.7%) C. albicans were still susceptible 
to fluconazole. However lower susceptibility patterns 
were noted in NACs especially in C. tropicalis (87.3%), 
C. parapsilosis (88.5%) and C. glabrata (53.8%). 
Candida albicans showed an MIC90 of 2 μg/mL, which 
is in the susceptible range. Conversely, C. tropicalis, C. 
parapsilosis and C. glabrata showed MIC90 values of 32, 
16, and 32 μg/mL, respectively. These values fell within 
the susceptible dose-dependent range. Therefore, it is 
advisable to give high-dose fluconazole if one wants to 
treat NAC candidaemia, particularly those caused by C. 
glabrata, C. tropicalis and C. parapsilosis. Apart from 
C. krusei which is known to be intrinsically resistant 
to fluconazole, the overall frequency of resistance to 
fluconazole was still low (6%). The highest fluconazole 
resistance rate was noted with C. tropicalis (9.1%). This 
finding was consistent with other reports from European 
studies (Tortorano et al. 2003; Zepelin et al. 2007). We 
found that of all nine fluconazole-resistant isolates, none 
of them were susceptible to voriconazole or itraconazole. 
Only 25% and 50% of these isolates were SDD to 
voriconazole and itraconazole, respectively. However, 
about 90 to 100% of them were still susceptible to 
amphotericin B, caspofungin and flucytosine. Therefore, 
we would advise against azoles for treatment if the isolate 
is known to be fluconazole-resistant. 
 All four major Candida species, viz. C. tropicalis, C. 
albicans, C. parapsilosis and C. glabrata (Table 1), showed 
reduced susceptibility to itraconazole, which is consistent 
with the previous study in our institution (Tzar & Shamim 
2009). The MIC90 of C. tropicalis and C. glabrata were 
highly elevated that they were categorized under the 
resistant category. Hence from our finding, itraconazole 
is not recommended for treatment of candidaemia. It can 
be used as an alternative agent for invasive aspergillosis, 
histoplasmosis or penicilliosis marneffei. 
 Although the majority of Candida species (94.7%) 
was still susceptible to amphotericin B with an MIC90 of 
1μg/mL, resistance towards amphotericin B was noted in 
several species including C. tropicalis, C. parapsilosis and 
C. glabrata (Table 2). No amphotericin B resistance was 
reported previously in UKMMC (Tzar & Shamim 2009). 
Thus, the fact that amphotericin resistance has emerged in 
our institution must be borne in mind whenever treatment 
failures occur with this drug.
 In our findings, flucytosine was found to be efficacious 
against all Candida isolates, with 97.4% of isolates were 
susceptible to it. This is probably due to lack of flucytosine 
fIgURE 1. Distribution of Candida species isolated form blood (2008 to 2010)
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exposure to our Candida isolates because it is mainly used 
to treat cryptococcosis. It is rarely used as monotherapy 
since it may lead to treatment failure and development 
of resistance (Hospenthal & Bennett 1998). In our study, 
flucytosine resistance that was seen in C. tropicalis and 
C. parapsilosis is consistent with a previous study done 
in Europe (Tortorano et al. 2003). 
 The newer drugs, caspofungin and voriconazole, were 
also found to be efficacious against all Candida species. 
Although 100% susceptible, C. parapsilosis had shown an 
elevated MIC90 of 2 μg/mL to caspofungin which was just 
one-dilution away from being resistant. Only one species 
was noted to show resistance to caspofungin which was 
C. tropicalis (1.8%) and three species to voriconazole; 
C. albicans (4.3%), C. glabrata (7.7%) and C. tropicalis 
(9.1%). Even so, the overall prevalence of caspofungin 
resistance among our Candida isolates was low (0.7%) 
and it remains the recommended drug against NAC. 
 In comparison to the previous study done in UKMMC, 
this study showed that the commonest age group with 
candidaemia had shifted from 61-70 to 51-60 years old 
(Tzar & Shamim 2009). However, the mean age remained 
the same at 46 years old. Infants were mostly affected by 
C. albicans, whereas the older age group by NACs. This 
trend was consistent with the results shown by the SENTRY 
Antimicrobial Surveillance Programme (1997-2000), in 
which the incidence of candidaemia caused by C. albicans 
decreased with age (Pfaller et al. 2002).
 Our results showed that most candidaemia cases were 
from the ICU, followed by surgical wards and medical 
wards. This result is similar to previous studies done in 
UKMMC (Tzar & Shamim 2009) and in Italy (Luzzaro et 
al. 2011). Patients in these wards usually have risk factors 
for candidaemia such as debilitating underlying conditions, 
prolonged hospital stay, exposure to many invasive 
procedures and various broad-spectrum antibiotics. 
Therefore, more stringent infection control measures should 
be in place in these locations. Interestingly, the number of 
Candida isolates from our ICU had decreased from 30.6% 
(2005-2006) to 19.9% in current study (Tzar & Shamim 
2009). This could be attributed to intensive infection 
control programmes such as hand hygiene surveillance, 
catheter care bundle and antibiotic stewardship that had 
taken place in our ICU since 2006. Another study in Latin 
America and North America also showed the same trend of 
decreasing frequency of candidaemia in their ICU settings 
(Pfaller et al. 2011). This trend was thought to be due to 
a decrease in the incidence of candidaemia caused by C. 
albicans; most probably as a result of increased use of 
fluconazole and preventive measures to curb bloodstream 
infections (Trick et al. 2002).
 In our study, C. tropicalis has surpassed C. albicans as 
the commonest species by 19.4% in 2009 and 2.6% in 2010 
(figure 1). In comparison, C. albicans was the predominant 
species in years 2005-2006, followed by C. tropicalis, C. 
parapsilosis and C. glabrata (Tzar & Shamim 2009). This 
trend is worrying because the morbidity and mortality 
rates were reported to be higher in C. tropicalis infection 
than C. albicans infection (Kothavade et al. 2010). The 
authors hypothesized that this might be due to additional 
C. tropicalis secretion, which could be highly cytotoxic 
in immunocompromised patients. In view of this, referral 
centres including UKMMC must be vigilant and administer 
fast and accurate treatment of candidaemia, especially the 
ones caused by C. tropicalis.
CONCLUSION
Candida tropicalis, C. albicans, C. parapsilosis and 
C. glabrata were the four most commonly isolated 
species causing candidaemia in our study. generally, 
all our Candida species showed a trend of reducing in 
vitro susceptibility towards all antifungal agents tested. 
Although resistance towards caspofungin was noted in 
this study, the percentage was still low. Thus, from the 
study, as reports of candidaemia and its geographical 
variations are becoming more common, local data on 
Candida epidemiology and susceptibility patterns are vital 
in management of candidaemia. 
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